VBI Vaccines Reports Rapid Seroprotection Results from an Interim Analysis of a Phase IV Postmarketing Study of its Sci-B-Vac® Hepatitis B Vaccine

By | Press Releases, Sci-B-Vac®
98.8% of Patients Seroprotected at Two Months Following Second Dose of Sci-B-Vac® VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”) today reported interim results from an ongoing Phase IV postmarketing study to evaluate Sci-B-Vac®, VBI’s licensed third-generation hepatitis B vaccine,...
Read More